Metabolic syndrome in patients with chronic hepatitis C virus genotype 1 infection who do not have obesity or type 2 diabetes

被引:21
|
作者
Magalhaes Oliveira, Lucivalda Pereira [1 ,2 ]
de Jesus, Rosangela P. [2 ]
Boulhosa, Ramona S. S. B. [1 ]
Mendes, Carlos Mauricio C. [1 ]
Lyra, Andre Castro [1 ,3 ,4 ]
Lyra, Luiz Guilherme C. [1 ,4 ]
机构
[1] Univ Fed Bahia, Postgrad Program, Salvador, BA, Brazil
[2] Univ Fed Bahia, Dept Nutr Sci, Salvador, BA, Brazil
[3] Univ Fed Bahia, Dept Med, Div Gastroenterol & Hepatol, Salvador, BA, Brazil
[4] Hosp Sao Rafael, Gastrohepatol Unit, Salvador, BA, Brazil
关键词
Metabolic Syndrome; Chronic Hepatitis C; Genotype; 1; Overweight; Insulin Resistance; INSULIN-RESISTANCE; OXIDATIVE STRESS; LIVER; STEATOSIS; MORTALITY; FIBROSIS; DISEASE; RISK;
D O I
10.6061/clinics/2012(03)03
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: The individual components of metabolic syndrome may be independent predictors of mortality in patients with liver disease. We aimed to evaluate the prevalence of metabolic syndrome and its related components in hepatitis C virus-infected patients who are not obese and do not have type 2 diabetes. METHODS: This cross-sectional study included 125 patients infected with hepatitis C virus genotype 1. Metabolic syndrome was defined according to the International Diabetes Federation. Anthropometric data were measured according to standardized procedures. Bioimpedance analysis was performed on all patients. RESULTS: Metabolic syndrome was diagnosed in 21.6% of patients. Of the subjects with metabolic syndrome, 59.3% had hypertension, 77.8% had insulin resistance, 85.2% were overweight, 48.1% had a high waist circumference, 85.2% had an increased body fat percentage, and 92.3% had an elevated waist: hip ratio. In the bivariate analysis, female sex (OR 2.58; 95% CI: 1.09-6.25), elevated gamma-glutamyl transferase (cGT) (OR 2.63; 95% CI: 1.04-7.29), elevated fasting glucose (OR 8.05; 95% CI: 3.17-21.32), low HDL cholesterol (OR 2.80; 95% CI: 1.07-7.16), hypertriglyceridemia (OR 7.91; 95% CI: 2.88-22.71), elevated waist circumference (OR 10.33; 95% CI: 3.72-30.67), overweight (OR 11.33; 95% CI: 3.97-41.07), and increased body fat percentage (OR 8.34; 95% CI: 2.94-30.08) were independent determinants of metabolic syndrome. Using the final multivariate regression model, similar results were observed for abdominal fat (OR 9.98; 95% CI: 2.63-44.41) and total body fat percentage (OR 8.73; 95% CI: 2.33-42.34). However, metabolic syndrome risk was also high for those with blood glucose >= 5.55 mmol/L or HDL cholesterol <0.9 mmol/L (OR 16.69; 95% CI: 4.64-76.35; OR 7.23; 95% CI: 1.86-32.63, respectively). CONCLUSION: Metabolic syndrome is highly prevalent among hepatitis C virus-infected patients without type 2 diabetes or obesity. Metabolic syndrome was significantly associated with hypertension, insulin resistance, increased abdominal fat, and overweight.
引用
收藏
页码:219 / 223
页数:5
相关论文
共 50 条
  • [31] Type 2 diabetes mellitus in chronic hepatitis C virus infection: risk factor or consequence?
    Abenavoli, Ludovico
    Rouabhia, Samir
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2013, 7 (04) : 295 - 297
  • [32] Sofosbuvir for Chronic Hepatitis C Virus Infection Genotype 1-4 in Patients Coinfected With HIV
    Rodriguez-Torres, Maribel
    Gaggar, Anuj
    Shen, Gong
    Kirby, Brian
    Svarovskaia, Evguenia
    Brainard, Diana
    Symonds, William T.
    McHutchison, John G.
    Gonzalez, Milagros
    Rodriguez-Orengo, Jose
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 68 (05) : 543 - 549
  • [33] ECONOMIC EVALUATION OF BOCEPREVIR FOR THE TREATMENT OF PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION IN HUNGARY
    Odhiambo, R.
    Chhatwal, J.
    Ferrante, S. A.
    El Khoury, A.
    Elbasha, E.
    VALUE IN HEALTH, 2012, 15 (07) : A390 - A390
  • [34] Risk factors for the development of diabetes mellitus in chronic hepatitis C virus genotype 4 infection
    Chehadeh, Wassim
    Abdella, Nabila
    Ben-Nakhi, Abdullah
    Al-Arouj, Monira
    Al-Nakib, Widad
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 (01) : 42 - 48
  • [35] Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection
    Asahina, Yasuhiro
    Itoh, Yoshito
    Ueno, Yoshiyuki
    Matsuzaki, Yasushi
    Takikawa, Yasuhiro
    Yatsuhashi, Hiroshi
    Genda, Takuya
    Ikeda, Fusao
    Matsuda, Takuma
    Dvory-Sobol, Hadas
    Jiang, Deyuan
    Massetto, Benedetta
    Osinusi, Anu O.
    Brainard, Diana M.
    McHutchison, John G.
    Kawada, Norifumi
    Enomoto, Nobuyuki
    LIVER INTERNATIONAL, 2018, 38 (09) : 1552 - 1561
  • [36] Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection
    Toyoda, Hidenori
    Chayama, Kazuaki
    Suzuki, Fumitaka
    Sato, Ken
    Atarashi, Tomofumi
    Watanabe, Tsunamasa
    Atsukawa, Masanori
    Naganuma, Atsushi
    Notsumata, Kazuo
    Osaki, Yukio
    Nakamuta, Makoto
    Takaguchi, Koichi
    Saito, Satoru
    Kato, Koji
    Pugatch, David
    Burroughs, Margaret
    Redman, Rebecca
    Alves, Katia
    Pilot-Matias, Tami J.
    Oberoi, Rajneet K.
    Fu, Bo
    Kumada, Hiromitsu
    HEPATOLOGY, 2018, 67 (02) : 505 - 513
  • [37] Impact of obesity on degree of liver disease and response to therapy in patients with chronic hepatitis C genotype 1 infection
    Cesario, K
    Khandwala, F
    Edwards, K
    Carey, W
    Barnes, D
    Zein, N
    GASTROENTEROLOGY, 2005, 128 (04) : A746 - A746
  • [38] Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes
    Lu, Jun
    Hou, Xuhong
    Tu, Hong
    Tang, Zhenghao
    Xiang, Yongbing
    Bao, Yuqian
    Gu, Jianren
    Jia, Weiping
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (04) : 619 - 625
  • [39] ASSOCIATION OF LIPID PROFILES WITH HEPATITIS C VIRAL LOAD IN CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1 AND 2 INFECTION
    Hsu, Ching-Sheng
    Liu, Chen-Hua
    Liu, Chun-Jen
    Lai, Ming-Yang
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    HEPATOLOGY, 2008, 48 (04) : 1180A - 1181A
  • [40] Clinical impact of genotype 1 TT virus infection in patients with chronic hepatitis C and response of TT virus to α-interferon
    Nishizawa, Y
    Tanaka, E
    Orii, K
    Rokuhara, A
    Ichijo, T
    Yoshizawa, K
    Kiyosawa, K
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2000, 15 (11) : 1292 - 1297